In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from Fierce Biotech, ranking the top 10 R&D budgets from 2024.
Did Merck hold on to its 2023 crown? And did any new faces crack this year’s list? Listen to find out!
To learn more about the topics in this episode:
This week's episode is brought to you by Cencora.
See omnystudio.com/listener for privacy information.
